Recent perspectives in topical therapy in superficial bladder cancer

Current Opinion in Urology

Volumn 9, Issue 5, 1999, Pages 407-411

  Böhle, Andreas ^a   Durek, Christoph ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

7 N [2 [[2 (GAMMA GLUTAMYLAMINO)ETHYL]DITHIO]ETHYL]MITOMYCIN C; BCG VACCINE; CYTOSTATIC AGENT; DOXORUBICIN; EPIRUBICIN; MITOMYCIN C; TRANSFERRIN;

BLADDER CANCER; CANCER IMMUNOTHERAPY; COST BENEFIT ANALYSIS; DRUG CYTOTOXICITY; HUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TOPICAL TREATMENT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BCG VACCINE; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-2; NEOPLASM RECURRENCE, LOCAL; PHOTOCHEMOTHERAPY; URINARY BLADDER NEOPLASMS;

EID: 0033398414     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-199909000-00007     Document Type: Review

References (42)

1. 1 Kurth K-H, Denis L, Ten Kate FJW, Sylvester R, De Pauw M, Bouffioux C, et al. Prognostic factors in superficial bladder tumors. Problem Urol 1992; 6:471-483.
2. 2 Lamm DL, Stogdill VD, Stogdill BJ, Crispen RG. Complications of bacillus Calmette-Guérin immunotherapy in 1278 patients with bladder cancer. J Urol 1986; 135:1352-1354.
3. 3 Wientjes GM, Dalton JT, Badalament RA, Drago JR, Au JL. Bladder wall penetration of intravesical mitomycin C in dogs. Cancer Res 1991; 51:4347-4354.
4. 4 Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MKB, Bijnens L. A combined analysis of European Organization for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol 1996; 156:1934-1941.
5. 5 Oosterlinck W, Kurth K-H, Schröder F, Bultinck J, Hammond B, Sylvester R and members of the European Organization for Research and Treatment of Cancer. A prospective European Organization for Research and Treatment of Cancer genitourinary group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993; 149:749-752.
6. 6 Tsushima T, Miyaji Y, Noda M, Nasu Y, Kumon H, Ohmori H. Absorption of epirubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer. Urol Int 1998; 60:161-164.
7. 7 Solomon LZ, Jennings AM, Hayes MC, Bass PS, Birch BR, Cooper AJ. Is gamma-linolenic acid an effective intravesical agent for superficial bladder cancer? In vitro cytotoxicity and in vivo tolerance studies. Urol Res 1998; 26:11-15.
8. 8 Solomon LZ, Jennings AM, Foley SJ, Birch BR, Cooper AJ. Bladder cancer recurrence by implantation of exfoliated cells: is γ-linolenic acid an effective tumoricidal agent? Br J Cancer 1998; 82:122-126.
9. 9 Bouffioux C, Kurth K-H, Bono A, Oosterlinck W, Kruger CB, Pauw M, Sylvester R. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing earty versus delayed instillations and short-term versus long-term treatment. J Urol 1995; 153:934-941.
10. 10 Okamura K, Kinukawa T, Tsumura Y, Oshima S. A randomized study of short versus long-term intravesical epirubicin instillation for superficial bladder cancer. Eur Urol 1998; 33:285-288.
11. 11 Rohde D, Raffenberg G, Kaviani S, Wolff J, Jakse G. T-N-(2-([2-(gamma-L-glutamylamino)-ethyl]-dithio)-ethyl)-mitomycin C (KW-2149) is more active than mitomycin C on chemonaive and drug-resistant urothelial carcinoma cells. Urol Res 1998; 26:243-247.
12. 12 Munns J, Yaxley J, Coomer J, Lavin MF, Gardiner RA, Watters D. Evaluation of the potential of transferrin-adriamycin conjugates in the treatment of bladder cancer. Br J Cancer 1998; 82:284-289. Transferrin-adriamycin conjugates were used to target transferrin receptor-positive cancer cells selectively in an in-vitro approach.
13. 13 Riedl CR, Knoll M, Plas E, Pfluger H. Intravesical electromotive drug administration technique: preliminary results and side effects. J Urol 1998; 159:1851-1856.
14. 14 Brausi M, Campo B, Pizzocaro G, Rigatti P, Parma A, Mazza G, et al. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative phase II study. Urology 1998; 51:506-509.
15. 15 Colombo R, Dapozzo LF, Lev A, Salonia A, Pavonemacaluso M. Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors. J Urol 1998; 159:783-787.
16. 16 Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 1991; 325:1205-1209.
17. 17 Lundholm C, Norlen BJ, Ekman P, Jahnson S, Lagerkvist M, Lindeborg T, et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. J Urol 1996; 156:372-376.
18. 18 Lebret T, Gaudez F, Herve JM, Barre P, Lugagne PM, Botto H, Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumors: recurrence, progression and success. Eur Urol 1998; 34:67-72.
19. 19 Baniel J, Grauss D, Engelstein D, Sella A. Intravesical bacillus Calmette-Guérin treatment for stage T1 grade 3 transitional cell carcinoma of the bladder. Urology 1998; 52:785-789.
20. 20 Lebret T, Becette V, Barbagelatta M, Herve JM, Gaudez F, Barre P, et al. Correlation between p53 overexpression and response to bacillus Calmette-Guérin therapy in a high-risk select population of patients with T1G3 bladder cancer. J Urol 1998; 159:788-791.
21. 21 Pages F, Flam TA, Vieillefond A, Molinie V, Abeille X, Lazar V, et al. P53 status does not predict initial clinical response to bacillus Calmette-Guérin intravesical therapy in T1 bladder tumors. J Urol 1999; 159:1079-1084.
22. 22 Orsola A, Palou J, Xavier B, Algaba F, Salvador J, Vicente J. Primary bladder carcinoma in situ: assessment of early BCG response as a prognostic factor. Eur Urol 1998; 33:457-463.
23. 23 Okamura T, Akita H, Kawai N, Tozawa K, Yamada Y, Kohri K. Immunohistochemical evaluation of p53, proliferating cell nuclear antigen (PCNA) and bcl-2 expression during bacillus Calmette-Guérin (BCG) intravesical instillation therapy for superficial bladder cancers. Urol Res 1998; 26:161-164.
24. 24 Jackson AM, Ivshina AV, Senko O, Kuznetsova A, Sundan A, O'Donnell MA, et al. Prognosis of intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndromes analysis. J Urol 1999; 159:1054-1063. IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, soluble intercellular adhesion molecule-1, TNF-α, sCD14, IFN-γ, granulocyte-macrophage colony-stimulating factor, volume and pH were analysed in the urine of BCG-treated patients. sCD1, TNF-α, sCD14 and pH were highly informative variables, suggesting the possibility of being able to predict an individual patient's outcome.
25. 25 Schamhart DHJ, Kurth K-H, De Reijke TM, Vleeming R. BCG treatment and the importance of an inflammatory response. Urol Res 1992; 20:199-203.
26. 26 Jackson AM, Alexandroff AB, Kelly RW, Skibinska A, Esuvaranathan K, Prescott S, et al. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy. Clin Exp Immunol 1995; 99:369-375.
27. 27 Zlotta AR, Drowart A, van Vooren J-P, Shekarsarai H, Cock MD, Pirson M, et al. Superficial bladder tumors and increased reactivity against mycobacterial antigens before bacillus Calmette-Guérin therapy. J Urol 1998; 159:1885-1891.
28. 28 Nouri AME, Symes MO. Relevance of the immune system in human urological malignancies: prospective for future clinical treatments. Urology 1998, 51 (Suppl. 5A):41-49.
29. 29 Böhle A, Durek C, Schäfer I, Brandau S, Ulmer AJ, Flad H-D, Jocham D. Die BCG-aktivierte Killerzelle: untersuchung spezifischer Erkennungs-und Tötungsmechanismen zur Charakterisierung des Wirkprinzips der intravesikalen Immuntherapie mit Bacillus Calmette-Guérin. Akt Urol 1998; 29:175-187.
30. 30 Poppas DP, Pavlovich CP, Folkman J, Vöst EE, Chen X, Luster AD, O'Donnell MA. Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10. Urology 1998; 52:268-275. The urinary output of antiangiogenic inducible protein 10 and IFN-γ post-BCG and in-vitro response to stimulation of human transitional and endothelial cells with BCG or IFN was determined. The results suggested that antiangiogenesis might indeed be involved in the mode of action of BCG.
31. 31 Jansson OT, Morcos E, Brundin L, Lundberg J, Söderhäll M, Wiklund NP. The role of nitric oxide in bacillus Calmette-Guérin mediated anti-tumour effects in human bladder cancer. Br J Cancer 1998; 78:588-592.
32. 32 Nemoto R, Nakamura I. Takahasi M, Abe C. Tuberculous enteritis after intravesical bacillus Calmette-Guérin therapy: a case of mistaken identity. J Urol 1998; 159:2091-2092.
33. 33 Damm O, Briheim G, Hagstrom T, Jönsson B, Skau T. Ruptured mycotic aneurysm of the abdominal aorta: a serious complication of intravesical instillation bacillus Calmette-Guérin therapy [Abstract]. J Urol 1998; 159:984-984.
34. 34 Böhle A, Kirsten D, Schröder K-H, Knipper A, Fornara P, Magnussen H, Jocham D. Clinical evidence of systemic persistence of bacillus Calmette-Guérin: long-term pulmonary bacillus Calmette-Guérin infection after intravesical therapy for bladder cancer and subsequent cystectomy. J Urol 1992; 148:1894-1897.
35. 35 Hurle R, Losa A, Ranieri A, Lembo A. Acid-fast bacilli persisting in the genitourinary tract 3 years after intravesical bacille Calmette-Guérin therapy for bladder carcinoma. Br J Urol 1998; 81:496-497.
36. 36 Barza MJ, Blum JH, Graemecook FM, Basgoz N. A 57-year-old man with fever and jaundice after intravesical instillation of bacille Calmette-Guérin for bladder cancer - granulomatous hepatitis due to intravesical instillation of BCG for urinary bladder carcinoma. N Engl J Med 1998; 339:831-837. A good presentation of a clinical case with a systemic BCG infection, involving possible differential diagnoses and diagnostic procedures.
37. 37 Witjes JA, van der Meijden APM, Sylvester CR, Debruyne FMJ, van Aubel A, Witjes WPJ. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. Urology 1998; 52:403-410. Long-term results of a clinical trial of BCG versus mitomycin C in an intermediate risk profile population are given. The efficacy of the two treatment policies were similar with regard to tumour recurrence.
38. 38 Lamm DL, Crawford ED, Blumenstein BA, Crissman JD, Montie JE, Gottesman J, et al. Maintenance BCG immunotherapy of superficial bladder cancer: a randomized prospective Southwest Oncology Group study [Abstract]. J Urol 1992; 147:A242.
39. 39 Den Otter W, Dobrowolski Z, Bugajski A, Papla B, van der Meijden APM, Koten JW, et al. Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J Urol 1998; 159:1183-1186.
40. 40 Nseyo UO, Shumaker B, Klein EA, Sutherland K. Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. J Urol 1998; 160:39-44.
41. 41 Wyld L, Reed MWR, Brown NJ. The influence of hypoxia and pH on aminolaevulinic acid-induced photodynamic therapy in bladder cancer cells in vivo. Br J Cancer 1999; 77:1821-1827. Cellular conditions of ALA-induced PDT were examined. The response to PDT was abolished by hypoxia, and PDT-induced cytotoxicity was enhanced at lower pH values. In biopsies, ALA-induced fluorescence of tumour tissue was twice that of normal urothelium in vitro and up to 10-fold in vivo.
42. 42 Sarosdy MF, Manyak MJ, Sagalowsky AI, Belldegrun A, Benson MC, Bihrle W III, et al. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin. Urology 1998; 51:226-231.